The challenge of genetic studies in hypertension

Circulation Research

Volumn 100, Issue 10, 2007, Pages 1389-1393

  Saavedra, Juan M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; COMPLEMENTARY DNA; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE; VASCULOTROPIN;

BINDING AFFINITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EDITORIAL; ENVIRONMENTAL FACTOR; ESSENTIAL HYPERTENSION; EXPERIMENTAL MOUSE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; MOLECULAR CLONING; NONHUMAN; POPULATION STRUCTURE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; NA(+)-K(+)-EXCHANGING ATPASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, INBRED DAHL; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; SEX CHARACTERISTICS;

EID: 34249655707     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000269420.81524.05     Document Type: Editorial

References (53)

1. McBride MW, Graham D, Delles C, Dominiczak AF. Functional genomics in hypertension. Curr Opin Nephrol Hypert. 2006;15:145-151.
2. Cowley AW. The genetic dissection of essential hypertension. Nat Rev Genet. 2006;7:829-840.
3. Garcia EA, Newhouse S, Caulfield MJ, Munroe PB. Genes and hypertension. Curr Pharmaceut Design. 2003;9:1679-1689.
4. Anonymous. Freely associating. Nat Genet. 1999;22:1-2.
5. Lalouel J-M, Rohrwasser A. Power and replication in case-control studies. Am J Hypertens. 2002;15:201-205.
6. Glorioso N, Herrera VLM, Bagamasbad P, Filigheddu F, Troffa C, Argiolas G, Bulla E, Decano JL, Ruiz-Opazo N. Association of ATP1A1 and Dear SNP-haplotypes with essential hypertension with gender-specific and haplotype-specific effects. Circ Res 2007;100:1522-1529.
7. Herrera VL, Xie HX, Lopez LV, Schork NJ, Ruiz-Opazo N. The α1 Na,K-ATPase gene is a susceptibility hypertension gene in the Dahl salt-sensitive HSD rat. J Clin Invest. 1998;102:1102-1111.
8. Kaneko Y, Cloix J-F, Herrera VLM, Ruiz-Opazo N. Corroboration of Dahl SQ276L α1 Na,K-ATPase protein sequence: impact on affinities for ligands and on E1 conformation. J Hypert. 2005;23:745-752.
9. Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VLM. Molecular characterization of a dual endothelin-1/Angiotensin II receptor. Mol Med. 1998;4:96-108.
10. Kaneko Y, Herrera VLM, Didishvili T, Ruiz-Opazo N. Sex-specific effects of dual ET-1/Ang II receptor (Dear) variants in Dahl SALT-sensitive/resistant hypertension rat model. Physiol Genom. 2005;20:157-164.
11. Ruiz-Opazo N, Akimoto K, Herrera VL. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat Med. 1995;1:1074-1081.
12. Ruiz-Opazo N, Lopez LV, Herrera VL. The dual Ang II/AVP receptor gene N119S/C163R variant exhibits sodium-induced dysfunction and cosegregates with salt-sensitive hypertension in the Dahl salt-sensitive hypertensive rat model. Mol Med. 2002;8:24-32.
13. Mobasheri A, Avila J, Cózar-Castellano, Brownleader MD, Trevan M, Francis MJO, Lamb JF, Martin-Vasallo P. Na+,K+-ATPase isozyme diversity: comparative biochemistry and physiological implications of novel functional interactions. Biosci Rep. 2000;20:51-91.
14. +-ATPase. Kidney Int. 2006;69:2148-2154.
15. +-K-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol. 2006;290:R524-R528.
16. Herrera VL, Emanuel JR, Ruiz-Opazo N, Levenson R, Nadal-Ginard B. Three differentially expressed Na,K-ATPase α subunit isoforms: structural and functional implications. J Cell Biol. 1987;105:1855-1865.
17. Ruiz-Opazo N, Barany F, Hirayama K, Herrera VL. Confirmation of mutant α 1 Na,K-ATPase gene and transcript in Dahl salt-sensitive/JR rats. Hypertension. 1994;24:260-270.
18. +-ATPase gene in the Dahl salt-sensitive rat. Hypertension. 1991;18:689-693.
19. +)-ATPase α 1 locus to cosegregate with blood pressure in Dahl rats. J Hypertens. 1990;8:457-462.
20. + ATPase in the Dahl S rat. J Hypertens. 2006;24:1209-1210.
21. Harris E, Barnard R. Reply to Herrera and Ruiz-Opazo's letter published in the June 2006 issue. J. Hypertens. 2006;24:2312-2313.
22. Herrera VLM, Ponce LRB, Bagamasbad PD, YanPelt BD, Didishvili T, Ruiz-Opazo N. Embryonic lethality in Dear gene-deficient mice: new player in angiogenesis. Physiol Genom. 2005;23:257-268.
23. Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the Yin and Yang on vascular function. Current Med Chem. 2006;13:1655-1665.
24. Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol. 2006;2:637-650.
25. Burry RW. Perspectives: Specificity Controls for Immunocytochemical Methods. J Histochem Cytochem. 2000;48:163-165.
26. Saper CB. An open letter to our readers on the use of antibodies. J Comp Neurol. 2005;493:477-478.
27. Kubo T, Hagiwara Y. Enhanced central hypertonic saline-induced activation of angiotensin II-sensitive neurons in the anterior hypothalamic area of spontaneously hypertensive and Dahl S rats. Brain Res Bull. 2006;68:335-340.
28. Blalock JE. Genetic origins of protein shape and interaction rules. Nat Med. 1995;1:876-878.
29. Houen G. Evolution of the genetic code: the nonsense, antisense, and antinonsense codes make no sense. Bio System. 1999;54:39-46.
30. Root-Bernstein RS. Peptide self-aggregation and peptide complementarity as bases for the evolution of peptide receptors: a view. J Mol Recognit. 2005;18:4049.
31. De Gasparo M, Whitebread S, Einsle K, Heusser C. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor? Biochem J Let. 1989;261:310-311.
32. Saavedra JM. Studies on genes and hypertension. A daunting task. J Hypertens. 2005;23:929-932.
33. Mondry A, Loh M, Liu P, Zhu A-L, Nagel M. Polymorphisms of the insertion/deletion ACE and M235 AGT genes and hypertension: surprising new findings and meta-analysis of data. BMC Nephrol. 2005;6:1-11.
34. Luft FC. Geneticism of essential hypertension. Hypertension. 2004;43:1-5.
35. Dutil J, Eliopoulos V, Tremblay J. Hamet P, Charron S, Deng AY. Multiple quantitative trait loci for blood pressure interacting epistatically and additively on Dahl chromosome 2. Hypertension. 2005;45:557-564.
36. Grondin M, Eliopoulos V, Lambert R. Deng Y, Ariyarajah A, Moujahidine M, Dutil J, Charron S, Deng AY. Complete and overlapping congenics proving the existence of a quantitative trait locus for blood pressure on Dahl rat chromosome 17 Physiol Genomics. 2005;21:112-116.
37. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-945.
38. Samani NJ. Genome scans for hypertension and blood pressure regulation. Am J Hypertens. 2003;16:167-171.
39. Dominiczak AF, Graham D, McBride MW, Brain NJ, Lee WK, Charchar FJ, Tomaszewski M, Delles C, Hamilton CA. Corcoran Lecture. Cardiovascular genomics and oxidative stress. Hypertension. 2005;45:636-642.
40. Michalkiewicz M, Michalkiewicz T, Ettinger RA, Rutledge EA, Fuller JM, Moralejo DH, Van Yserloo B, MacMurray AJ, Kwitek AE, Jacob HJ, Lander ES, Lernmark A. Transgenic rescue demonstrates involvement of the lan5 gene in T cell development in the rat. Physiol Genomics. 2004;19:228-232.
41. Pravenec M, Landa V, Zidek V, Musilova A, Kazdova L, Qi N, Wang J, St Lezin E, Kurtz TW. Transgenic expression of CD36 in the spontaneously hypertensive rat is associated with amelioration of metabolic disturbances but has no effect on hypertension. Physiol Res. 2003;52:681-688.
42. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, Mueller M, Hummel O, Monti J, Zidek V, Musilova A, Kren V, Causton H, Game L, Born G, Schmidt S, Muller A, Cook SA, Kurtz TW, Whittaker J, Pravenec M, Aitman TJ. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet. 2005;37:243-253.
43. Kardia SLR. Context-dependent genetic effects in hypertension. Curr Hypertens Reports. 2000;2:32-38.
44. Farahani P, Dolovich L, Levine M. Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension. J Clin Epidemiol. 2007;60:1-7.
45. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension. 2003;41:207-210.
46. Terwilliger JD, Haghighi F, Hiekkalinna TS, Göring HHH. A biased assessment of the use of SNPs in human complex traits. Curr Opin Genet Dev. 2002;12:726-734.
47. Hamet P Merlo E, Seda O, Broeckel U, Tremblay J, Kaldunski M, Gaudet D, Bouchard G, Deslauriers B, Gagnon F, Antoniol G, Pausova Z, Labuda M, Jomphe M, Gossard F, Tremblay G, Kirova R, Tonellato P, Orlov SN, Pintos J, Platko J, Hudson TJ, Rioux JD, Kotchen TA, Cowley AW Jr. Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. Am J Hem Genet. 2005;76:815-832.
48. Boerwinkle E. All for one and one for all: introduction to a coordinated analysis of the Gly 460-Trp a-adducin polymorphism. Am J Hypertens. 2000;3:734-735.
49. Couser WG, Drueke T, Halloran P, Kasiske B, Klahr S, Morris P. Uniform clinical trial registration policy for journals of kidney diseases, dialysis, and transplantation. J Am Soc Nephrol. 2005;16:837.
50. 1 receptor molecular aspects. In: Unger T, Scholkens BA, eds. Angiotensin Vol I. New York: Springer-Verlag Berlin Heidelberg; 2004:269-295.
51. Breu V, Hashido K, Broger C, Miyamoto C, Furuichi Y, Hayes A, Kalina B, Loffler BM, Ramuz H, Clozel M. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur J Biochem. 1995;231:266-270.
52. Adachi M, Hashido K, Trzeciak A, Watanabe T, Furuichi Y, Miyamoto C. Functional domains of human endothelin receptor. J Cardiovasc Pharmacol. 1993;22(Suppl 8):S121-S124.
53. Krystek SR Jr., Patel PS, Rose PM, Fisher SM, Kienzle BK, Lach DA, Liu EC, Lynch JS, Novotny J, Webb ML. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. J Biol Chem. 1994;269:12383-12386.